Lafutidine

拉呋替丁

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLafutidine
Drug Alias Name拉夫替丁lafutidina拉福替丁lafutidinelafutidinum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H2 receptor antagonists
TargetsHistamine H2 receptor
Therapy Area/IndicationsStomach UlcerDuodenal UlcerPeptic Ulcer +[4] 
Global Approved IndicationsStomach UlcerDuodenal UlcerGastroesophageal Reflux
Approved Indications in ChinaStomach UlcerDuodenal Ulcer
Original Approved Country/TerritoryJapan
Original Approved Date2000/01/08
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesTaiho Pharmaceutical Co LtdSichuan Kelun Pharmaceutical Co Ltd
Inactive CompaniesUcb Pharma
Active IndicationsStomach UlcerDuodenal UlcerPeptic Ulcer +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeA02BA08
Related LinksWikipediaDrugBankKEGG